<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3787">
  <stage>Registered</stage>
  <submitdate>25/01/2013</submitdate>
  <approvaldate>25/01/2013</approvaldate>
  <nctid>NCT01779791</nctid>
  <trial_identification>
    <studytitle>A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma</studytitle>
    <scientifictitle>An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-004097-26</secondaryid>
    <secondaryid>CR100956</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PCI-32765 (Ibrutinib)

Experimental: PCI-32765 (Ibrutinib) - 


Treatment: drugs: PCI-32765 (Ibrutinib)
560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint>Up to 2 years after the last patient is enrolled</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>Every 12 weeks during the first 96 weeks, followed by every 24 weeks thereafter until disease progression (up to 2 years after the last patient is enrolled)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>Up to progressive disease, death, lost to follow-up, withdrawal of consent, or study end (up to 2 years after the last patient is enrolled)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Up to death, lost to follow-up, withdrawal of consent, or study end (up to 2 years after the last patient is enrolled)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to response</outcome>
      <timepoint>Every 12 weeks during the first 96 weeks, followed by every 24 weeks thereafter until disease progression (up to 2 years after the last patient is enrolled)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients experiencing resolution of lymphoma-related B symptoms</outcome>
      <timepoint>Day 1 of every cycle during the first 12 months, thereafter every other cycle (up to 2 years after the last patient is enrolled)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients identified with blood biomarkers that alter B-cell receptor signaling or activate alternative signaling pathways</outcome>
      <timepoint>Day 1 of Cycles 1-3, and time of disease progression, or at end-of treatment visit for patients who discontinue treatment without disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum plasma concentration of PCI-32765</outcome>
      <timepoint>Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oral plasma clearance of PCI-32765</outcome>
      <timepoint>Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oral volume of distribution at steady state of PCI-32765</outcome>
      <timepoint>Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma-concentration time curve of PCI-32765</outcome>
      <timepoint>Pre-dose Day 1 of Cycles 1-3, post-dose Day 1 of Cycles 1, 2 at 1, 2, and 4 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants affected by an adverse event</outcome>
      <timepoint>Up to 30 days after the last dose of study medication</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologic proof of Grade 1, 2, or 3a follicular lymphoma (FL) without clinical or
             pathological evidence of transformation

          -  Previously treated with at least 2 prior lines of therapy, including at least 1
             rituximab combination chemotherapy regimen; last prior line of therapy includes an
             anti CD20 monoclonal antibody-containing chemotherapy regimen (separate lines of
             therapy are defined as different regimens that are either separated by disease
             progression, refractory disease, or relapsed disease)

          -  Resistant disease to the last therapy, defined as progression of disease during or
             within 12 months of the last dose of chemotherapy in a CD20 antibody combination
             chemotherapy regimen

          -  At least 1 measurable site of disease according to International Working Group Revised
             Response Criteria for Malignant Lymphoma

          -  Eastern Cooperative Oncology Group performance status grade 0 or 1

          -  Hematology and biochemical laboratory values must be within protocol-defined
             parameters within 7 days prior to enrollment

          -  Agrees to protocol-defined use of effective contraception

          -  Women of childbearing potential must have a negative serum or urine pregnancy test at
             screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer
             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation
             therapy or other investigational agents within 3 weeks, or major surgery within 4
             weeks of first dose of study drug

          -  Prior treatment with PCI-32765 or other Bruton's tyrosine kinase inhibitors (patients
             who progressed or became refractory while on treatment with PI3K inhibitors are
             excluded)

          -  Concurrent enrollment in another therapeutic investigational clinical treatment study

          -  Received a prior allogeneic hematopoietic stem cell transplant (prior autologous
             hematopoietic stem cell transplant is allowed)

          -  Known central nervous system lymphoma

          -  History of prior malignancy (except malignancy treated with curative intent and with
             no known active disease present for &gt;=3 years before enrollment, adequately treated
             non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately
             treated cervical carcinoma in situ without evidence of disease)

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists

          -  Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification

          -  Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis
             C or active infection with Hepatitis B or any uncontrolled active systemic infection
             requiring intravenous antibiotics

          -  Women who are pregnant or breastfeeding

          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the patient's safety, interfere with the
             absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue
             risk</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>17/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>110</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Concord</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Milton</hospital>
    <hospital> - Prahran</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Milton</postcode>
    <postcode> - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Courrière</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Marbella</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Pharmacyclics LLC.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib)
      administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01779791</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>